Kesmalea Therapeutics

London, United Kingdom · Founded 2020 · Privately Held (backing)

Developer of a pipeline of therapeutics designed to transform large protein degraders into small molecules for targeted protein degradation. Kesmalea Therapeutics is based in London, United Kingdom and was founded in 2020. Its last known valuation is $39 million. It has raised $37.8 million.

Last price · $/share
—
Implied valuation
$39.0M
Total raised
$37.8M
Last round
—
What is Kesmalea Therapeutics worth?
$39.0Mlast known valuation
Free account
More of Kesmalea Therapeutics with a free account
  • ·Watch Kesmalea Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Kesmalea Therapeutics funding history

No rounds on record

No funding rounds for Kesmalea Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Kesmalea Therapeutics valuation

Kesmalea Therapeutics's last known valuation is $39 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How Kesmalea Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Kesmalea Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →

Frequently asked about Kesmalea Therapeutics

What is Kesmalea Therapeutics worth?
Kesmalea Therapeutics's last known valuation is $39.0M.
How much has Kesmalea Therapeutics raised?
Kesmalea Therapeutics has raised $37.8M in total funding across its recorded rounds.